An Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects

RDD Pharma

Status and phase

Completed

Phase 2

Phase 1

Conditions

Fecal Incontinence

Treatments

Drug: coated suppository

Study type

Interventional

Funder types

Industry

Identifiers

NCT01265485

RDD 107

Details and patient eligibility

About

This is an open label, dose-finding, 2-parts study. Approximately 6 subjects will be participating in this study. This study is composed of 2 parts:

Part 1 is a dose finding study. Part 2 is a pharmacodynamic and pharmacokinetic study of an elected dose. A screening will be used to determine patients' suitability for inclusion in the trial. Within one week after the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will enter part 1 of the study, one day of dose escalation. During this part, patients will undergo rectal manometry to determine anal pressure at baseline. Afterwards coated suppositories at various drug concentrations will be inserted and follow up manometries will be performed to determine response.

Patients that presented with an increase in rectal resting pressure without adverse events will enter the second part of the study. In this part, patients will be administered with a coated suppository, at a dose found at part 1 of the study to cause significant anal contraction. Manometry studies will be performed before insertion (baseline) and at 1, 3 and 5 hours after insertion.

Blood levels for drug concentrations will be taken at times 0, 30, 60, 120, 180, 300 minutes after administration and rectal manometries will be done at times 0, 1, 3 and 5 hours after administration.

Enrollment

6 estimated patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Signed written informed consent.
Male or female subjects 18 to 55 years of age;

Exclusion criteria

Known allergy to the active drug or excipients.
Pregnancy or lactation.
Active cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;
Type 1 diabetes mellitus;
Insulin treated type 2 diabetes mellitus;
Renal insufficiency.
Liver insufficiency.
Malignant disease within 5 years of screening;
History of rectal surgery.
History of HIV, hepatitis B, hepatitis C.
Has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula, infection or space occupying lesion.
Chronic use of medications with the exception of birth control pills.